Trial
NCT04636814
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Chiesi Farmaceutici S.p.A.
Collaborators
—
Condition
Chronic Obstructive Pulmonary Disease
Intervention
CHF6001 1600µg
Why stopped
Strategic decision by Sponsor; not due to safety reasons
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-02-02